• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Viloxazine (Qelbree): A Faster Strattera?

Viloxazine (Qelbree): A Faster Strattera?

May 20, 2021
Joshua Feder, MD, and Talia Puzantian, PharmD, BCPP.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Joshua Feder, MD, and Talia Puzantian, PharmD, BCPP. Dr. Feder and Dr. Puzantian have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
On April 2 viloxazine, brand name Qelbree, received an FDA indication for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents ages 6–17 years. Viloxazine is a norepinephrine reuptake inhibitor, similar to atomoxetine (Strattera), which was approved in 2008. Atomoxetine, while approved for ADHD, has some disadvantages when compared with stimulants. It is generally less effective, with response rates only about 50%–75% of typical stimulants. And it is slow, usually taking 2–4 weeks to kick in, as opposed to a day or two for stimulants. Does viloxazine have the same disadvantages? Let’s look at the data that have been reported so far.

Viloxazine has been studied for various indications since the 1970s. It originally received an FDA orphan drug designation (less rigorous than approval) for narcolepsy and was studied for nocturnal enuresis and depression, though it did not gain approval for either indication.

For their Phase III studies of viloxazine in ADHD, Supernus Pharmaceuticals (Qelbree’s manufacturer) performed four short-term, six- to eight-week randomized controlled trials (Nasser A et al, Clin Ther 2020;42(8):1452–1466). 1,013 children and adolescents (ages 6–17) were randomly assigned to various doses of viloxazine (100–600 mg per day) or placebo. Measures included the ADHD Rating Scale-5 (ADHD-RS-5) and the Weiss Functional Impairment Rating Scale-Parent (WFIRS-P): assessments of symptom severity and functional impairment, respectively. In one of the studies, patients taking viloxazine 400 mg daily improved significantly more than those assigned to placebo; however, the 600 mg dose did not reach statistical significance.

What about speed of response? In one study, patients assigned to viloxazine 400 mg began to show improvement over placebo by week 1—more quickly than most studies of atomoxetine, which generally separates from placebo around week 3. Viloxazine has not been compared head-to-head with stimulants or with atomoxetine, so its comparative efficacy is unknown, but it’s clearly slower than stimulants, with a clinically meaningful onset similar to atomoxetine beginning at 2–4 weeks.

The viloxazine studies have been criticized because the researchers completed the study then used a crossover mapping from the original outcome scales—the ADHD-RS-5 and WFIRS-P—to the Clinical Global Impression Scale. Such “post hoc” analyses often find positive results that may not be valid.

Side effects
Viloxazine’s side effects, like other norepinephrine reuptake inhibitors, included sedation, mania, increased blood pressure and heart rate, and suicidal ideation. Six out of the 1,013 patients reported suicidal ideation, 1 reported suicidal behavior, and 2 patients reported both suicidal ideation and behavior for a total of 9 patients (0.9%). Two control patients reported suicidal ideation (0.4%), though there were no completed suicides in either group. Irritability and insomnia were more common in the viloxazine group, with 4% reporting insomnia (vs 1% in placebo) and 3% reporting irritability (1% in placebo). Viloxazine is a potent inhibitor of CYP1A2 and is contraindicated with duloxetine, ramelteon, tasimelteon, tizanidine, and theophylline. 

Dosing
Viloxazine is supplied in dosages of 100, 150, and 200 mg extended-release capsules. It takes 2 days for this preparation to reach steady-state blood levels, and there is a ~10% reduction in absorption if viloxazine is taken with a high-fat meal or if the capsules are opened and sprinkled on applesauce. The recommended dosage for children 6–11 years old is 100 mg once daily, titrated as needed weekly by 100 mg increments to a maximum of 400 mg. For 12- to 17-year-olds, the starting dosage is 200 mg and can be titrated weekly in 100 mg increments up to 400 mg.

Any advantages over atomoxetine?
The preliminary data reported in press releases show that viloxazine may work a little bit faster than atomoxetine. But there’s no reason to expect it to be any more effective in the long run, nor do we expect it to compare favorably to stimulants.

Cost
Supernus has not released the price of Qelbree as of this writing; however, they claim that it will be competitively priced.

CCPR’s Take
Viloxazine is the second norepinephrine reuptake inhibitor to be approved for ADHD. It’s not clear if it has any advantage over atomoxetine, though if its reputed faster onset of action is better substantiated, it may be advantageous. As with atomoxetine, you should monitor patients for suicidality, mania, and drug interactions.
Child Psychiatry
KEYWORDS cgi clinical-global-impressions post-hoc-analysis-adhd-rating-scale-5 qelbree viloxazine weiss-functional-impairment-rating-scale-parent-wfirs-p
Joshua Feder, MD,

More from this author
Talia Puzantian, PharmD, BCPP.

New Generic Versions of Naloxone

More from this author
www.thecarlatreport.com
Issue Date: May 20, 2021
SUBSCRIBE NOW
Table Of Contents
Welcome to the 21st Century Cures Act Information Sharing Rules
ECT in Severe Adolescent Mood ­Disorders
The Effect of Age and Pubertal Stage on Mental Health in Gender-Incongruent Youths
Note From the Editor-in-Chief
Approaches to Autism Intervention
Effect Size Matters: The Seismic Shift Toward Naturalistic and Developmental Interventions in Autism
Viloxazine (Qelbree): A Faster Strattera?
Pharmacotherapy for Autism Spectrum Disorder
CME Post-Test - Autism in Children and Adolescents, CCPR, April/May/June 2021
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    (PRE-ORDER) Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto52138604.jpg
    Child Psychiatry

    Readily Available and Easily Abused Over-the-Counter Medications

    Reviewing four commonly abused substances that are legally available for purchase: Dextromethorphan, antihistamines, pseudoephedrine, and Kratom.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.